Breast Cancer Drugs Market Size, Share & Growth 2031

Segments - Breast Cancer Drugs Market by Types (Hormonal Receptors, Mitotic Inhibitors, HER2 Inhibitors, Anti-metabolites, CDK 4/6 Inhibitors, and Aromatase Inhibitors), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

Breast Cancer Drugs Market Outlook 2031

The Breast Cancer Drugs Market size was USD 26.4 Billion in 2022 and is likely to reach USD 54.56 Billion by 2031, expanding at a CAGR of 8.4% during 2023–2031. The growth of the market is attributed to the increasing prevalence of diseases coupled with emerging novel therapies.

For effective management of breast cancer the early detection is a key factor. Early detection of disease gives desired outcomes such as increasing number of treatment options, raising survival rate, and improves quality of life.

Based on an article 2018 Research Fast Facts was published by Susan G. Komen, stated that regular screening and early detection reduces the death rate by 30%.

Breast Cancer Drugs Market Key Takeaways

Based on International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, in women, breast cancer is fifth major cause responsible for deaths, which is around 626,989 deaths each year. As per the American Cancer Society, in 2018, around 266,000 new cases were diagnosed in women in U.S. Moreover, aging is one of the highest risk factors.

As per Cancer Treatment Centers of America, breast cancer in women above 60 years of age are possibly diagnosed and only around 10-12% of cases were found in women less than 45 years of age. Huge presence of disease along with expiry of patent are key factors responsible for increasing investment in R&D of novel products.

The R&D expenditure from companies such as Merck & Co. Inc., Pfizer, Sanofi, Johnson & Johnson Services Inc., AbbVie Inc., GlaxoSmithKline plc., and Celgene Corporation are rising significantly, but sudden fall is noted for AstraZeneca, Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd, Novartis Company.

Breast Cancer Drugs Market Trends, Drivers, Restraints, and Opportunities

Growing prevalence of disease is major factor responsible for propelling the market growth over the forecast period.
Increasing concern for effective treatment and management, and rising investment of key players in research and innovation are anticipated to drive the market growth.
Growing number of pipelined drugs and rising research and development of novel drugs are projected to fuel the growth of the market.
Environmental factors, new generation treatments and bio-similar versions, changing lifestyle, physical inactivity, and hormonal changes are some factors responsible for driving the market expansion.
Rising new treatment methods and therapies is expected to boost the market growth over the forecast period.
Stringent regulations, expiry of the patented drugs, and prolonged therapies degrading the health are anticipated to hamper the market growth.
Lack of accessibility of medical attention and less awareness about healthcare among people are projected to impede the market expansion.

Scope of The Breast Cancer Drugs Market Outlook Report

The report on the global breast cancer drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Breast Cancer Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Types (Hormonal Receptors, Mitotic Inhibitors, HER2 Inhibitors, Anti-metabolites, CDK 4/6 Inhibitors, and Aromatase Inhibitors)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	F. Hoffmann-La Roche Ltd.; Novartis AG; AbbVie, Inc.; AstraZeneca; Eli Lilly and Company; Celgene Corporation; Biocon; Merck & Co., Inc.; Genzyme Corporation; Janssen Global services LLC; MacroGenics, Inc.; Celldex Therapeutics; Onyx Pharmaceuticals Inc.; and BioNumerik Pharmaceuticals, Inc.

Breast Cancer Drugs Market Segment Insights

HER2 inhibitors segment is projected to hold a major market share

Based on types, the breast cancer drugs market is segmented into hormonal receptors, mitotic inhibitors, HER2 inhibitors, anti-metabolites, CDK 4/6 inhibitors, and aromatase inhibitors. The HER2 inhibitors segment is expected to hold a key share of the market during the forecast period owing to rising incidence of HER2 positive breast cancer.

As per article published in 2013, by F. Hoffman La Roche Ltd., one out of five women were diagnosed the breast tumor would have HER2 positive cancer. In addition, demand is rapidly increasing from emerging countries such as Asia Pacific and Latin America which is projected to propel the segment growth over the forecast period.

However, the CDK 4/6 inhibitor segment is anticipated to expand at a rapid pace during the forecast period. These drugs are anticipated to increase the patient’s survival rate having metastatic breast cancer.

North America is anticipated to dominate the market

On the basis of regions, the breast cancer drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to rising awareness among people and increasing presence of established R&D infrastructure.

Furthermore, presence of major market players such as Merck & Co., Inc.; AbbVie, Inc.; Pfizer, Inc.; and Celgene Corporation in the region is projected to boost the regional market growth. On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years. Globally, demand of drugs is increasing which results in growing manufacturing and R&D facilities by manufacturers in this region.

Initiatives taken by several organizations to educate people, raise funds, and create awareness about disease is expected to fuel the regional market growth.

Segments

The global breast cancer drugs market has been segmented on the basis of

Types

Hormonal Receptors
Mitotic Inhibitors
HER2 Inhibitors
Anti-metabolites
CDK 4/6 Inhibitors
Aromatase Inhibitors

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

F. Hoffmann-La Roche Ltd.
Novartis AG
AbbVie, Inc.
AstraZeneca
Eli Lilly and Company
Celgene Corporation
Biocon
Merck & Co., Inc.
Genzyme Corporation
Janssen Global services LLC
MacroGenics, Inc.
Celldex Therapeutics
Onyx Pharmaceuticals Inc.
BioNumerik Pharmaceuticals, Inc.

Competitive Landscape

Key players competing in the breast cancer drugs market are F. Hoffmann-La Roche Ltd.; Novartis AG; AbbVie, Inc.; AstraZeneca; Eli Lilly and Company; Celgene Corporation; Biocon; Merck & Co., Inc.; Genzyme Corporation; Janssen Global services LLC; MacroGenics, Inc.; Celldex Therapeutics; Onyx Pharmaceuticals Inc.; and BioNumerik Pharmaceuticals, Inc.

Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, in March 2017, Kisqali was approved by the Food and Drug Administration (FDA) for HR+/HER2 which was the first-line treatment for metastatic breast cancer along with an aromatase inhibitor.

Breast Cancer Drugs Market By Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Breast Cancer Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Breast Cancer Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Breast Cancer Drugs Market - Supply Chain
  4.5. Global Breast Cancer Drugs Market Forecast
     4.5.1. Breast Cancer Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Breast Cancer Drugs Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Breast Cancer Drugs Market Absolute $ Opportunity
5. Global Breast Cancer Drugs Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Breast Cancer Drugs Market Size and Volume Forecast by Types
     5.3.1. Hormonal Receptors
     5.3.2. Mitotic Inhibitors
     5.3.3. HER2 Inhibitors
     5.3.4. Anti-metabolites
     5.3.5. CDK 4/6 Inhibitors
     5.3.6. Aromatase Inhibitors
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Breast Cancer Drugs Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Breast Cancer Drugs Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Breast Cancer Drugs Demand Share Forecast, 2019-2026
7. North America Breast Cancer Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Breast Cancer Drugs Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Breast Cancer Drugs Market Size and Volume Forecast by Types
     7.4.1. Hormonal Receptors
     7.4.2. Mitotic Inhibitors
     7.4.3. HER2 Inhibitors
     7.4.4. Anti-metabolites
     7.4.5. CDK 4/6 Inhibitors
     7.4.6. Aromatase Inhibitors
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Breast Cancer Drugs Demand Share Forecast, 2019-2026
8. Latin America Breast Cancer Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Breast Cancer Drugs Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Breast Cancer Drugs Market Size and Volume Forecast by Types
     8.4.1. Hormonal Receptors
     8.4.2. Mitotic Inhibitors
     8.4.3. HER2 Inhibitors
     8.4.4. Anti-metabolites
     8.4.5. CDK 4/6 Inhibitors
     8.4.6. Aromatase Inhibitors
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Breast Cancer Drugs Demand Share Forecast, 2019-2026
9. Europe Breast Cancer Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Breast Cancer Drugs Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Breast Cancer Drugs Market Size and Volume Forecast by Types
     9.4.1. Hormonal Receptors
     9.4.2. Mitotic Inhibitors
     9.4.3. HER2 Inhibitors
     9.4.4. Anti-metabolites
     9.4.5. CDK 4/6 Inhibitors
     9.4.6. Aromatase Inhibitors
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Breast Cancer Drugs Demand Share Forecast, 2019-2026
10. Asia Pacific Breast Cancer Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Breast Cancer Drugs Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Breast Cancer Drugs Market Size and Volume Forecast by Types
     10.4.1. Hormonal Receptors
     10.4.2. Mitotic Inhibitors
     10.4.3. HER2 Inhibitors
     10.4.4. Anti-metabolites
     10.4.5. CDK 4/6 Inhibitors
     10.4.6. Aromatase Inhibitors
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Breast Cancer Drugs Demand Share Forecast, 2019-2026
11. Middle East & Africa Breast Cancer Drugs Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Breast Cancer Drugs Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Breast Cancer Drugs Market Size and Volume Forecast by Types
     11.4.1. Hormonal Receptors
     11.4.2. Mitotic Inhibitors
     11.4.3. HER2 Inhibitors
     11.4.4. Anti-metabolites
     11.4.5. CDK 4/6 Inhibitors
     11.4.6. Aromatase Inhibitors
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Breast Cancer Drugs Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Breast Cancer Drugs Market: Market Share Analysis
  12.2. Breast Cancer Drugs Distributors and Customers
  12.3. Breast Cancer Drugs Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. F. Hoffmann-La Roche Ltd.
     12.4.2. Novartis AG
     12.4.3. AbbVie, Inc.
     12.4.4. AstraZeneca
     12.4.5. Eli Lilly and Company
     12.4.6. Celgene Corporation
     12.4.7. Biocon
     12.4.8. Merck & Co., Inc.
     12.4.9. Genzyme Corporation
     12.4.10. Janssen Global services LLC